Optimizing drug exposure to minimize selection of antibiotic resistance

Clinical Infectious Diseases

Volumn 45, Issue SUPPL. 2, 2007, Pages

  Olofsson, Sara K ^a   Cars, Otto ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; ENOXACIN; ENROFLOXACIN; FOSFOMYCIN; LOMEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL TRANSMISSION; CLINICAL PRACTICE; CONFERENCE PAPER; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG INHIBITION; DRUG MECHANISM; ENVIRONMENTAL FACTOR; ESCHERICHIA COLI; HOST SELECTION; HUMAN; HYGIENE; IN VITRO STUDY; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SALMONELLA ENTERICA; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS;

EID: 34548265066     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/519256     Document Type: Conference Paper

References (66)

1. World Health Organization. Shaping the future, World Health report 2003. 2003. Available at: http://www.who.int/whr/2003/en/whr03_en.pdf.
2. Ball P, Baquero F, Cars O, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002; 49:31-40.
3. DeRyke CA, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs 2006; 66:1-14.
4. Andersson DI, Hughes D. Muller's ratchet decreases fitness of a DNA-based microbe. Proc Natl Acad Sci U S A 1996; 93:906-7.
5. Drake JW, Charlesworth B, Charlesworth D, Crow JF. Rates of spontaneous mutation. Genetics 1998; 148:1667-86.
6. Hall LM, Henderson-Begg SK. Hypermutable bacteria isolated from humans - a critical analysis. Microbiology 2006; 152:2505-14.
7. Miller JH. Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair. Annu Rev Microbiol 1996; 50:625-43.
8. Schaaff F, Reipert A, Bierbaum G. An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46:3540-8.
9. Giraud A, Matic I, Radman M, Fons M, Taddei F. Mutator bacteria as a risk factor in treatment of infectious diseases. Antimicrob Agents Chemother 2002; 46:863-5.
10. Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003; 47:3222-32.
11. Gustafsson I, Sjölund M, Torell E, et al. Bacteria with increased mutation frequency and antibiotic resistance are enriched in the commensal flora of patients with high antibiotic usage. J Antimicrob Chemother 2003; 52:645-50.
12. Reynolds MG. Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 2000; 156:1471-81.
13. Nagaev I, Björkman J, Andersson DI, Hughes D. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol Microbiol 2001; 40:433-9.
14. Johanson U, Aevarsson A, Liljas A, Hughes D. The dynamic structure of EF-G studied by fusidic acid resistance and internal revertants. J Mol Biol 1996; 258:420-32.
15. Björkman J, Nagaev I, Berg OG, Hughes D, Andersson DI. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 2000; 287:1479-82.
16. Andersson DI, Levin BR. The biological cost of antibiotic resistance. Curr Opin Microbiol 1999; 2:489-93.
17. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 2003; 47:2850-8.
18. Gustafsson I, Cars O, Andersson DI. Fitness of antibiotic resistant Staphylococcus epidermidis assessed by competition on the skin of human volunteers. J Antimicrob Chemother 2003; 52:258-63.
19. Björkman J, Andersson DI. The cost of antibiotic resistance from a bacterial perspective. Drug Resist Updat 2000; 3:237-45.
20. Sherman DR, Mdluli K, Hickey MJ, et al. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996; 272:1641-3.
21. Sander P, Springer B, Prammananan T, et al. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 2002; 46:1204-11.
22. Sjölund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med 2003; 139:483-7.
23. Sjölund M, Tano E, Blaser MJ, Andersson DI, Engstrand L. Persistence of resistant Staphylococcus epidermidis after single course of clarithromycin. Emerg Infect Dis 2005; 11:1389-93.
24. Björkman J, Hughes D, Andersson DI. Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci USA 1998; 95:3949-53.
25. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31:1054-60.
26. Marchbanks CR, McKiel JR, Gilbert DH, et al. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection. Antimicrob Agents Chemother 1993; 37:1756-63.
27. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37:483-90.
28. Stearne LE, van Boxtel D, Lemmens N, Goessens WH, Mouton JW, Gyssens IC. Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses. Antimicrob Agents Chemother 2004; 48:1688-98.
29. Wiuff C, Lykkesfeldt J, Svendsen O, Aarestrup FM. The effects of oral and intramuscular administration and dose escalation of enrofloxacin on the selection of quinolone resistance among Salmonella and coliforms in pigs. Res Vet Sci 2003; 75:185-93.
30. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279:365-70.
31. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:747-50.
32. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2:289-300.
33. Baquero F, Negri MC, Morosini MI, Blazquez J. The antibiotic selective process: concentration-specific amplification of low-level resistant populations. Ciba Found Symp 1997; 207:93-105; discussion 105-11.
34. Negri MC, Lipsitch M, Blazquez J, Levin BR, Baquero F. Concentration-dependent selection of small phenotypic differences in TEM β-lactamase-mediated antibiotic resistance. Antimicrob Agents Chemother 2000; 44:2485-91.
35. Oh H, Nord CE, Barkholt L, Hedberg M, Edlund C. Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone. Infection 2000; 28:272-7.
36. Brunner M, Derendorf H, Muller M. Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Curr Opin Pharmacol 2005; 5:495-9.
37. Cars O. Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. Scand J Infect Dis Suppl 1990; 74:23-33.
38. Cars O, Ogren S. Antibiotic tissue concentrations: methodological aspects and interpretation of results. Scand J Infect Dis Suppl 1985; 44:7-15.
39. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents 2002; 19:355-8.
40. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55:601-17.
41. Zinner SH, Lubenko IY, Gilbert D, et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 2003; 52:616-22.
42. Allen GP, Kaatz GW, Rybak MJ. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int J Antimicrob Agents 2004; 24:150-60.
43. MacGowan AP, Rogers CA, Holt HA, Bowker KE. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2003; 47:1088-95.
44. Olofsson SK, Geli P, Andersson DI, Cars O. Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli. Antimicrob Agents Chemother 2005; 49:5081-91.
45. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42:521-7.
46. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36(Suppl 1):S42-50.
47. Odenholt I, Gustafsson I, Löwdin E, Cars O. Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model. Antimicrob Agents Chemother 2003; 47:518-23.
48. Negri MC, Morosini MI, Loza E, Baquero F. In vitro selective antibiotic concentrations of β-lactams for penicillin-resistant Streptococcus pneumoniae populations. Antimicrob Agents Chemother 1994; 38:122-5.
49. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001; 33(Suppl 3):S147-56.
50. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis 2007; 44:681-8.
51. Low DE. Antimicrobial drug use and resistance among respiratory pathogens in the community. Clin Infect Dis 2001; 33(Suppl 3):S206-13.
52. Marcusson LL, Olofsson SK, Komp Lindgren P, Cars O, Hughes D. Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother 2005; 55:938-43.
53. Drlica K, Zhao X, Blondeau JM, Hesje C. Low correlation between MIC and mutant prevention concentration. Antimicrob Agents Chemother 2006; 50:403-4.
54. Smith HJ, Walters M, Hisanaga T, Zhanel GG, Hoban DJ. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother 2004; 48:3954-8.
55. Smith HJ, Nichol KA, Hoban DJ, Zhanel GG. Stretching the mutant prevention concentration (MPC) beyond its limits. J Antimicrob Chemother 2003; 51:1323-5.
56. Zhao X. Clarification of MPC and the mutant selection window concept. J Antimicrob Chemother 2003; 52:731; author reply 732-3.
57. Livermore DM. Overstretching the mutant prevention concentration. J Antimicrob Chemother 2003; 52:732; author reply 732-3.
58. Dong Y, Zhao X, Domagala J, Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:1756-8.
59. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 2003; 52:11-7.
60. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45:433-8.
61. Allen GP, Kaatz GW, Rybak MJ. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47:2606-14.
62. Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1604-13.
63. Cui J, Liu Y, Wang R, Tong W, Drlica K, Zhao X. The mutant selection window in rabbits infected with Staphylococcus aureus. J Infect Dis 2006; 194:1601-8.
64. Olofsson SK, Marcusson LL, Komp Lindgren P, Hughes D, Cars O. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 2006; 57:1116-21.
65. Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 1995; 15:279-91.
66. Dong Y, Zhao X, Kreiswirth BN, Drlica K. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44:2581-4.